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The human cardiac sodium channel (hNav1.5, encoded by the SCN5A gene) is critical for
action potential generation and propagation in the heart. Drug-induced sodium channel
inhibition decreases the rate of cardiomyocyte depolarization and consequently conduction
velocity and can have serious implications for cardiac safety. Genetic mutations in hNav1.5
have also been linked to a number of cardiac diseases. Therefore, off-target hNav1.5 inhi-
bition may be considered a risk marker for a drug candidate. Given the potential safety
implications for patients and the costs of late stage drug development, detection, and mit-
igation of hNav1.5 liabilities early in drug discovery and development becomes important.
In this review, we describe a pre-clinical strategy to identify hNav1.5 liabilities that incorpo-
rates in vitro, in vivo, and in silico techniques and the application of this information in the
integrated risk assessment at different stages of drug discovery and development.
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INTRODUCTION
Cardiovascular safety is a principal concern in drug development
because undesired drug effects can have serious consequences for
cardiovascular physiology, impacting vital processes such as heart
rhythm, contractility, cardiac output, blood pressure, and end
organ perfusion. Indeed, cardiovascular safety is the leading cause
of post market drug withdrawal in the US (Piccini et al., 2009).
A drug candidate’s proarrhythmic risk is thus of signiﬁcant con-
cern throughout drug development. Much of this concern is based
on experience over the past several decades with compounds that
block the human ether-à-go-go related gene (hERG) potassium
channel. Abundant pre-clinical and clinical observations have
established a clear relationship between hERG blockers, a risk for
drug-induced QT prolongation, and Torsades de Pointes (TdP),
a potentially lethal cardiac arrhythmia (Heist and Ruskin, 2010;
Van Noord et al., 2010). It is also recognized that drug-induced
effects at other cardiac ion channels can result in serious adverse
cardiovascular effects (Chen et al., 2009). This has spurred phar-
maceutical companies to implement routine screening of drug
candidates against a panel of cardiac ion channels early in drug
development, and there is an increasing need in understanding
how results of these pre-clinical screens translate into clinical safety
risks in patients (Cao et al., 2010;Gintant et al., 2011;Harmer et al.,
2011).
The cardiac sodium channel (hNav1.5, encoded by the SCN5A
gene) is responsible for electrical excitation of atrial and ventric-
ular myocytes. Voltage-dependent opening of the channel drives
the upstroke of the cardiac action potential (phase 0), which initi-
ates cellular depolarization and propagates the action potential
throughout the cardiac chambers (George et al., 1995; Balser,
2001; Keating and Sanguinetti, 2001). Sodium channel inhibition
decreases the rate of cardiac depolarization and consequently slows
conduction velocity.Dependingon themagnitude,hNav1.5 block-
ade may manifest as PR interval prolongation and/or QRS com-
plex widening on the electrocardiogram (ECG;VaughanWilliams,
1992; Bode-Schnurbus et al., 2003; Hummel et al., 2009; Gintant
et al., 2011).
It is important to note that drug related effects on sodium
channels can also modify cardiac repolarization. For example,
decreased inactivation of the sodium inward current can pro-
long the action potential (Balser, 2001). Also, inhibition of cardiac
sodium channels can mitigate hERG channel blocking effects
of drugs as shown for the antipsychotic compound clozapine
(Warner and Hoffmann, 2002). Furthermore, sodium channel
inhibition can lead to impairment of cardiac contractility due to
reduced cytosolic free calcium concentrations mediated by the
Na+/Ca2+ exchanger (Ito et al., 1996; Larbig et al., 2010).
In general, sodium channels are susceptible to blockade by a
wide variety of small molecules, some of which are used clinically
as local anesthetics, anticonvulsants, antidepressants, and antiar-
rhythmics (Freedman and Steinberg, 1991; Graf, 2001; Thana-
coody andThomas, 2005).Many of these drugs are associatedwith
serious adverse reactions including cardiac arrhythmias (Vieweg
and Wood, 2004).
A considerable body of data indicates that drug induced
or genetic alterations of the cardiac sodium channel can have
important cardiovascular consequences. Genetic mutations in the
SCN5A gene underlie a number of cardiac diseases with diverse
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phenotypes (Tfelt-Hansen et al., 2010). Congenital loss and gain
of function mutations in SCN5A can both increase arrhythmia
risk. For example, loss of function mutations in SCN5A cause
Brugada syndrome while gain of function mutations cause long
QT syndrome type 3. Moreover, a striking lesson learned from
pharmacologically induced hNav1.5 inhibition came in the form
of the cardiac arrhythmia suppression trial (CAST), which tested
the hypothesis that suppressing ventricular premature complexes
in patients after myocardial infarction would improve survival.
Rather than the expected beneﬁt, CAST treatment arms using
encainide or ﬂecainide were associated with increased mortality
due to arrhythmias (Echt et al., 1991).
Off-target hNav1.5 channel inhibition is considered a risk
marker for a drug candidate. However, some uncertainty remains
regarding the implications of QRS widening and its translation to
pro-arrhythmic risk. While having a wide QRS appears to con-
fer arrhythmic risk in certain target patient populations with left
(Sumner et al., 2009) or right bundle branch block (Adesanya
et al., 2008), the relationship between QRS interval prolongation
and arrhythmias in patients without underlying heart disease is
less clear (Seger, 2006).
Given the weight of evidence regarding the adverse safety risks
and impact of cardiac sodium channel inhibition, detection, and
mitigation of hNav1.5 blockade is an important shared goal in the
pharmaceutical industry. In this review, we describe our current
pre-clinical strategy incorporating in vitro, in vivo, and in silico
techniques to identify the potential of new drug candidates for
hNav1.5 blockade and its electrophysiological consequences. We
also discuss examples of how to apply these results in an integrated
risk assessment at different stages of drug discovery.
REGULATORY GUIDANCE
The two relevant regulatory documents that provide guidance for
investigating drug effects on cardiac ion channels are Interna-
tionalConferenceonHarmonization (ICH)guidance for industry:
S7A Safety pharmacological studies for human pharmaceuticals
(ICH S7A) and S7B Non-clinical Evaluation of the Potential for
Delayed Ventricular Repolarization by Human Pharmaceuticals
(ICH S7B1). But, in contrast to regulatory precedents regarding
the rapid delayed rectiﬁer potassium current (IKr) and its relation-
ship to the electrocardiographic QT interval, evaluation of effects
on the cardiac sodium channel on changes in electrocardiographic
PR, and QRS intervals are not addressed in detail. ICH S7A states
that effects of the test substance on the ECG including effects on
conduction abnormalities should be evaluated.
ICH S7B describes the role of sodium channels during phase
0 and phase 1 of the action potential. Although testing for effects
on the cardiac sodium channel is not mentioned explicitly in the
primary testing strategy, this issue is addressed in the Follow up
Studies section, where the potential for inhibition of non-hERG
cardiac ion channels and their possible role inmitigating IKr effects
on action potential duration (APD) and QT interval are men-
tioned. For in vivo experiments, measurements of PR interval and
QRS duration are recommended in ICH S7B.
1http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html
PRE-CLINICAL ASSESSMENT
IN VITRO ASSAYS AND IN SILICO TOOLS
Patch-clamp
A common initial step in pre-clinical cardiac safety evaluation
is the in vitro assessment of effects of compounds on ion chan-
nel activity in recombinant expression systems using patch-clamp
electrophysiology. Conventional manual patch-clamp from single
cells with GigaOhm seals is the gold standard technology. How-
ever, the throughput of conventional electrophysiology assays is
too low to meet drug discovery project needs and requires highly
trained personnel. Recent developments in automated patch-
clamp technologies have enabled high throughput proﬁling of
compounds during early stages of drug discovery (Dunlop et al.,
2008; Harmer et al., 2008; Castle et al., 2009; Chen et al., 2009; Cao
et al., 2010). Biophysical properties and pharmacological proﬁles
obtained from automated hNav1.5 assays show good concordance
with manual patch-clamp recordings (Harmer et al., 2008; Cas-
tle et al., 2009; Cao et al., 2010). Because many clinically used
sodium channel blockers are state-dependent modulators, eval-
uation of state dependence is an important part of pre-clinical
safety risk assessment (Cao et al., 2010). Automated patch-clamp
assays have also been shown to recognize state-dependent modu-
lators for the hNav1.5 channel (Harmer et al., 2008; Castle et al.,
2009; Cao et al., 2010). While many competing technologies are
available, Novartis has utilized the IonWorks Quattro™system
(Molecular Devices, part of MDS Analytical Technologies) for
hNav1.5 proﬁling for several years (Cao et al., 2010). The assay
is used routinely as part of an integrated pre-clinical cardiac ion
channel safety assessment during phase transitions such as lead
nomination and clinical candidate selection. Lead candidate pro-
ﬁling has allowed prioritization of chemical series based on effects
on cardiac ion channels, including hNav1.5, and subsequently the
informed selection of compounds without signiﬁcant ion channel
safety liabilities for further development. When hNav1.5 activity
is identiﬁed within a chemical series, the assay is used to investi-
gate structure activity relationships (SAR) and to guide medicinal
chemistry efforts for mitigation of hNav1.5 channel inhibition
during lead optimization.
Several limitations of automated patch-clamp systems should
be kept in mind. Physicochemical properties of compounds such
as hydrophobicity and solubility can limitmeasurement of the true
inhibitory potency. Particularly for the IonWorks Quattro system,
the lack of a ﬂuid outlet and other technical limitations conﬁnes
this system to single time point readings making it unsuitable for
kinetic proﬁling (Cao et al., 2010). To study inhibition kinetics
and reversibility, additional manual patch-clamp assays may be
required. In this context, manual patch-clamp experiments com-
plement the data generated from automated experiments, which
helps deﬁne a precise channel-compound interaction, allows mea-
suring actual concentrations of the test compound in the recording
chamber and recordings at physiological temperatures.
While factors that directly modulate ionic channel proteins
can be explored using patch-clamp assays, indirect modulation
through mechanisms like gene expression or protein trafﬁcking
requires different techniques. Alterations in the hNav1.5 expres-
sion levels have been associated with acquired cardiac disorders,
such as heart failure (Rook et al., 2012). Cardiac sodium channel
Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research January 2012 | Volume 3 | Article 6 | 2
Erdemli et al. Pre-clinical cardiac sodium channel assessment
blockers have also been shown to facilitate trafﬁcking of mutant
hNav1.5 proteins in patientswith LongQTSyndrome type 3 (Ruan
et al., 2010). However, to our knowledge there are no reports of
small molecule inhibitors of hNav1.5 that act by altering channel
trafﬁcking and thereby cause delayed ECG changes in conduction
in vivo.
In silico tools and structure activity trends in the patch-clamp data
Since implementation of the automated patch-clamp hNav1.5
assay at Novartis, 1945 compounds across a range of different
targets have been tested and 148 of these showed inhibition of
the hNav1.5 channel (IC50< 10μM). Using ICM (version 3.7-2c,
MolSoft. LLC), these compounds were clustered (at the 0.2 Tani-
moto level) into 895 clusters. Of the 895 clusters, 90 clusters have
at least 1 member that is a hNav1.5 inhibitor (IC50< 10μM). To
analyze the SAR, RDKit’s radius= 3 Morgan count ﬁngerprints
hashed into a vector of size 1024 (RDKit: Open-source chemin-
formatics2) was used. The data set was analyzed for the effects
of small, lead optimization-sized changes which were deﬁned as
a Manhattan distance of 70 or less in the Morgan count ﬁnger-
prints. Because each individual observed change is not statistically
signiﬁcant, a quantitative structure activity relationship (QSAR)
model was constructed to help identify trends. Figure 1 shows
three selected chemical changes that had a dramatic effect on
hNav1.5 blockade potency and follow the trends observed in the
data. The ﬁrst observed change (Figure 1A)was the replacement of
the aliphatic cyclopentyl chainwith aliphatic chainwith hydroxyls.
The replacement of the carboxylic acid benzothiazolewith another
aryl system (many of the examples have a heteroatom closer to
the acid group) reduced the hNav1.5 inhibition (Figure 1B). The
2http://www.rdkit.org
FIGURE 1 | Modest changes in chemical structure can substantially
reduce hNav1.5 inhibition.Three selected chemical changes that
substantially reduce hNav1.5 inhibitory potency are shown. In each change
the portion of the molecule unaffected by the change is noted with an R.
The chemical change is annotated with the change in hNav1.5 IC50 values
measured with automated patch-clamp. (A) the replacement of the
aliphatic cyclopentyl chain with aliphatic chain with hydroxyls. (B) the
replacement of the carboxylic acid benzothiazole with pyridyl carboxylic
acid. (C) the addition of a sulfone to a phenyl group.
addition of a sulfone to a phenyl group which itself is at the end
of aliphatic tail (Figure 1C) reduced hNav1.5 blockade.
With only 1945 compounds measured to date, it is still early
in the exploration of hNav1.5 blockade and there is much more
SAR left to be discovered. Although hNav1.5 SAR is overall much
less promiscuous than the SAR for the hERG channel, some of
approaches that are useful for mitigation of hERG also apply
(Jamieson et al., 2006; Papadatos et al., 2010). For example, reduc-
ing the logP of compounds, and adding hydroxyls to greasy motifs
reduce hNav1.5 blockade.
Cardiac tissue and isolated heart preparations
Building on the proﬁling established through automated or man-
ual patch-clamp assays, cardiac sodium channel blocking effects of
drug candidates can be further evaluated in vitro using cardiac tis-
sues and isolated heart preparations. Acute pharmacologic effects
can be assessed by measuring QRS interval from the ECG in Lan-
gendorff perfused hearts and arterially perfused left ventricular
wedge preparations (Lu et al., 2010). Hondeghem et al. (2003)
demonstrated that the SCREENIT model (rabbit heart) could
properly characterize prototypical class IA, IB and IC sodium
channel blockers (e.g., quinidine, lidocaine, and ﬂecainide). Lu
et al. (2010) showed that these models can differentiate the pro-
arrhythmic effects of sodium channel blockers that affect cardiac
conduction. For example, in isolated left ventricular wedge prepa-
rations, ﬂecainide increased QRS interval in a rate-dependent
manner, and elicited ventricular tachycardia. On the other hand,
lidocaine only slightly increased QRS duration without inducing
ventricular tachycardia (Lu et al., 2010). Similarly in isolated rab-
bit hearts, ﬂecainide was associated with a marked increase in QRS
interval and ventricular tachycardia, whereas, lidocaine produced
a small increase in QRS duration and did not induce ventricular
tachycardia (Lu et al., 2010). In addition to providing data about
Nav1.5 liabilities, the isolated heart and wedge preparations are
also useful to evaluate compounds that have effects on multiple
cardiac ion channels and pro-arrhythmia potential.
While the rabbit ventricular wedge and isolated rabbit heart
models are useful for assessing Nav 1.5 dependent electrophysio-
logic effects of compounds in early drug discovery, these models
have limitations as well. These assays have low throughput and
require highly trained individuals. The results are subject to dis-
crepancies comparable to other in vitro and in vivo models due
to species speciﬁc physiology and pharmacology, differences in
assay conditions (e.g., perfusion time, recording frequencies, and
temperature) and residual effects of anesthetics (Lu et al., 2007;
Chen et al., 2009). Such models may also require relatively large
quantities of compounds if high concentrations need to be tested,
limiting their routine use in the very early stages of drug discovery.
At Novartis, we use the isolated rabbit heart model on a case-by-
case basis for mechanistic studies when there are discrepancies
between in vitro and in vivo results or if there are pro-arrhythmia
concerns.
IN VIVO ANIMAL MODELS
Cardiac sodium channel liability should be further evaluated
in vivo using conscious and in some cases anesthetized animal
models. In conscious animal models, Nav1.5 blocking risk is
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routinely assessed by evaluating QRS and PR intervals on the
ECG. The ECG can be recorded continuously in conscious,
non-restrained dogs or monkeys with an implanted telemetry
transmitter or using an external jacket (non-invasive telemetry).
In anesthetized models, intracardiac recordings like the His bun-
dle electrogram (HBE) can be obtained and provide valuable
functional information. However, several caveats must be con-
sidered for anesthetized animals. Since conditions are only stable
for a few hours, such experiments provide only a limited time
window to evaluate a drug effect. Thus, Nav1.5 blocking effects
due to metabolites or myocardial accumulation of the parent
compound may be missed. In addition, some general anesthetics
such as pentobarbital can affect cardiac conduction at anesthetic
concentrations and may confound results. A recent study eval-
uated the value of several in vivo pre-clinical models to predict
the cardiac sodium blocking risk in human (Heath et al., 2011).
Translation of ﬂecainide- or mexiletine-induced cardiac sodium
channel inhibition and slowing of ventricular conduction from
pre-clinical models to the clinic was assessed using conscious
telemetered rat, dog, and anesthetized dog models. Effects of ﬂe-
cainide and mexiletine in conscious dogs were comparable to the
ECG effects observed in patients and healthy volunteers. The anes-
thetized dog was least sensitive for detecting QRS changes. This
study concluded that the conscious dog was the most predictive
model for detecting effects of compounds on cardiac conduc-
tion as compared to conscious rat telemetry or anesthetized dog
models.
At Novartis, we routinely use external jacket telemetry in con-
scious dogs or monkeys in the ﬁrst non-rodent toxicity studies
to detect compound related ECG changes that may be due to
blockade of Nav1.5. We may also employ invasive telemetry in
conscious dogs or monkeys at this early stage to better char-
acterize equivocal or relatively small ECG effects observed in
previous studies. For some compounds, the ﬁrst in vivo evi-
dence of sodium channel blocking effect at low drug exposures
may be PR interval prolongation without QRS prolongation (see
compounds NVP-3, NVP-4, and NVP-6 in Table 1). For the
PR interval it is important to differentiate between a sodium
channel blocker and a calcium channel blocker. This can be
achieved by testing the activity of compounds on the cardiac
calcium channel (hCav1.2) in vitro as well as recording intrac-
ardiac conduction intervals in anesthetized dogs. The AH and
HV intervals are measured (Inoue and Zipes, 1987) to further
assess drug effects on the cardiac conduction system. The AH
interval is measured from the earliest onset of rapid right atrial
activity to the onset of the His potential and largely repre-
sents conduction time through the atrioventricular (AV) node.
The HV interval is measured from the onset of the His bun-
dle deﬂection to the beginning of ventricular depolarization and
represents infra Hisian conduction from below the AV node to
ventricular myocardium. Cardiac sodium channel blockers are
associated with QRS and PR interval prolongation on the ECG
and HV interval prolongation; in contrast, typical ﬁndings for
calcium channel blockers include PR prolongation on the ECG
and AH interval prolongation (Pressler et al., 1995). In addi-
tion, calcium channel blockers often lower blood pressure and
cause AV block at high doses, observations that are uncommon
for Nav1.5 blockers (Takahara et al., 2001). While several dis-
ease models (in vitro and in vivo torsade de pointes models) have
been developed to assess the pro-arrhythmic/torsadogenic poten-
tial of compounds that inhibit IKr and prolong the QT interval,
analogous models have not been validated for compounds that
inhibit cardiac sodium channel and result in the PR and/or QRS
prolongation.
MODELING AND SIMULATION
Mathematical models were ﬁrst introduced to describe the nerve
action potential in the squid giant axon (Hodgkin and Huxley,
1952). Subsequently, they have evolved to describe electrical exci-
tation of cardiac tissues (for a historical perspective see Noble
and Rudy, 2001), and have provided mechanistic insight into how
pharmacologically or genetically mediated perturbations affect
electrophysiology from the single ion channel level to the whole
heart. Current cellular mathematical models describe the electri-
cal activity of a single cell by relating the transmembrane potential
difference to the function of different ion channels (e.g., sodium
ﬂux through the hNav1.5 channel), exchangers (e.g., Na+/Ca2+)
and electrogenic pumps (e.g.,Na+/K+ATPase). The sodium chan-
nel current has been modeled extensively under normal physi-
ological conditions and in disease states (Moreno et al., 2011).
Advances in molecular biology have enabled researchers to iso-
late, build, and analyze models for congenital defects in channel
proteins (Clancy and Rudy, 2002; Starmer et al., 2003a) that com-
plement models of pharmacological drug effects (Starmer et al.,
2003b).
Early models treated cardiac sodium channel inhibition as a
simple reduction in conductance. However, more recent mod-
els incorporate components that address more complex state-
dependent ligand-channel interactions that are crucial to explain-
ing the observed behavior of certain drugs. A good example
of how modeling has provided translational insight into how
sodium channel inhibition can result in life-threatening ven-
tricular arrhythmias was provided in analyzing the results from
the CAST clinical trial. Modeling studies suggested clear links
between cardiac sodium channel inhibition, the arrhythmogenic
vulnerable period, and increase in ectopic activity (Starmer et al.,
1991, 1992). These and other studies (Starmer et al., 2003b) indi-
cate that hNav1.5 inhibition with a small molecule can induce
pro-arrhythmia, particularly in patients with underlying ischemic
heart disease.
Mathematical models have been useful in predicting the com-
plex effects of drugs which inhibit multiple cardiac ion channels.
For example, a model was developed to quantitatively predict the
degree of sodium channel blockade required to offset the effects
of a hERG channel blocker on action potential prolongation in
canine Purkinje ﬁbers (Bottino et al., 2006). The estimated IC50
values for hNav1.5 inhibition were subsequently conﬁrmed with
data from independent patch-clamp experiments (Bottino et al.,
2006). Novartis use models in conjunction with patch-clamp data
fromhERG,hNav1.5 andhCav1.2 channels to then conduct virtual
action potential and tissue conduction simulations to determine
the integrated concentration response in advance of or in parallel
with in vitro and in vivo proﬁling experiments on a case-by-case
basis.
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Table 1 | Pre-clinical profiles of compounds with cardiac sodium channel liability.
hNav1.51 (IC50, μM) Isolated heart2,3 (conduction @ μM) In vivo telemetry3,4
PR interval (@ Cmax5, μM) QRS duration (@ Cmax5, μM)
NVP-1 93Q ↓ (30) ↑ (19.7) ↑ (19.7)
NVP-2 4.5M NT ↑ (4.8) ↑ (4.8)
NVP-3 3.5Q NT ↑ (0.07) NE (1.9)
NVP-4 16M ↓ (9) ↑ (1.2) ↑ (1.9)
NVP-5 2.4M NT ↑ (0.22) ↑ (0.22)
NVP-6 >100M,6 NE(30) ↑ (4.5) ↑ (13.7)
NVP-7 41Q ↓ (90) ↑ (0.14) ↑ (0.14)
NVP-8 366M,7 ↓ (900) NE (43) NE (43)
NVP-9 >30Q,8 NT ↑ (1.2) ↑ (1.2)
NVP-10 >300M,9 NT ↑ (20.6) ↑ (20.6)
1Patch-clamp (Q: quattro, M: manual). In the absence of manual patch-clamp data Quattro assay results are presented. 2Isolated rabbit heart using SCREENIT model
(Hondeghem, 1994). 3All animal studies have been approved by the Novartis Animal Care and Use Committee. 4Non-rodent telemetry (dog or non-human primate).
5Free Cmax. 6No inhibition at 100μM. 7IC25 =91μM. 8Twenty-four percent current inhibition at 30μM, the highest concentration tested. 9Twenty-six percent current
inhibition at 300μM, the highest concentration tested. NT, not tested; NE, no effect.
CLINICAL EVALUATION OF PHARMACOLOGICALLY
MEDIATED EFFECTS ON hNAV1.5
Because the clinical manifestations of inhibiting cardiac sodium
channel canbequite variable, clinical assessment of suchmolecules
should be approached carefully. ECG or Holter telemetry assess-
ments are fundamental tools, and changes such as PRprolongation
or QRS widening can give indications of cardiac sodium chan-
nel inhibition. A catheter-based clinical electrophysiology study
may also be performed when a sodium channel blocker may be
expected to elicit changes similar to those reported in non-rodent
studies: prolongation of PR and/or QRS on the 12 lead ECG,
and prolongation of the AH and/or HV intracardiac intervals.
While studies have established a precedent for clinical evaluation
of sodium channel blockers using invasive catheter studies (Heath
et al., 2011), only limited data exist and do not clearly address
when an invasive approach is warranted. Similarly, there are lim-
ited data available regarding the relative sensitivity and speciﬁcity
of the PR,QRS,AH, and HV intervals when applied as biomarkers
for hNav1.5 blockade. Ultimately, clinical assessment strategies
should not only focus on standard measurements like the PR
and QRS intervals, but also consider relevant factors including
pharmacokinetics, safety margins, comorbidities, and concomi-
tantmedications. In addition, the strategy should be tailored to the
speciﬁc development program and the target population account-
ing for the relative risks and beneﬁts of invasive procedures like
catheter electrophysiology studies in humans.
RECENT NOVARTIS EXPERIENCE WITH THE PRE-CLINICAL
ASSESSMENT OF hNAV1.5 AND CLINICAL TRANSLATION
We have applied the pre-clinical testing strategies described above
over the past several years, and exemplary results are summarized
in Table 1. Five of tenNovartis compounds that were tested in vitro
in the hNav1.5 patch-clamp assay, were also tested in the isolated
rabbit heart model. Four of these 5 compounds showed conduc-
tion slowing, indicative of sodium channel inhibition. NVP-6,
which was inactive in the patch-clamp assay (no inhibition of the
hNav1.5 current at 100μM) also failed to induce any signiﬁcant
conduction effects in the isolated heart model at 30μM (the high-
est concentration tested). Overall the data show good correlation
between the patch-clamp and the isolated heart assays.
All 10 compounds were studied using the in vivo non-rodent
telemetry model; of these 10 compounds, 9 induced PR interval
prolongation and/or QRS widening (Table 1). One compound,
NVP-8, did not produce any signiﬁcant effect on the ECG, with
the caveat that the in vivo exposure achieved was limited. In con-
trast, NVP-6 and NVP-10 induced ECG changes in vivo, but did
not produce a high degree of hNav1.5 inhibition in vitro. The rea-
sons for this discrepancy are not known,but potential explanations
include species differences, metabolites that may be more potent
hNav1.5 inhibitors, in vivo faster heart rate and accumulation of
the compound in cardiac tissue in vivo. It is also possible that
the differences between the recombinant and native channel may
contribute to this discrepancy. The patch-clamphNav1.5 assay uti-
lizes humanembryonic kidney cells (HEK293) that overexpress the
pore forming alpha subunit of the human cardiac sodium channel.
This construct notably lacks the β subunits and other associated
proteins, which are known to regulate activity of hNav1.5 (Abriel,
2007). Though there are no known small molecule examples, it is
plausible that compounds may act thorough ancillary proteins.
Such effects may be underestimated or missed entirely in the
patch-clamp assay, but would be revealed in vivo. This scenario
underscores the importance of integrating both in vitro and in vivo
assays for the pre-clinical assessment of sodium channel liability.
Overall, these ﬁndings suggest that in vitro assays correlate reason-
ably well with in vivo non-rodent telemetry model results, but also
draw attention to circumstances where assays may be insensitive
or provide disparate results.
Although our longitudinal experience is limited to date, the
case of NVP-4 illustrates how pre-clinical ﬁndings can translate
into the clinical realm. NVP-4 had no signiﬁcant effect on hERG
(at 30μM) or on hCav1.2 (at 30μM) currents, but blocked the
hNav1.5 channels with an IC50 of 15.8μM in the patch-clamp
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assay. In the rabbit isolated heart model, NVP-4 was tested at con-
centrations ranging between 0.3 and 30μM. At concentrations
≥9μM, conduction velocity decreased and ventricular tachycar-
dia were observed (Table 1). In a single dose safety pharmacology
dog telemetry study, dose dependent PR prolongation and QRS
widening were observed without signiﬁcant changes in QT inter-
val duration (Figure 2). A 6% PR prolongation was observed at
a free Cmax of 1.2μM, and a 28% PR prolongation accompanied
by a 23% QRS widening at a free Cmax of 1.9μM (Table 1). The
Nav1.5 inhibition (PR and/or QRS prolongation) was also evident
in a 4week general toxicity study in dogs at a free Cmax range of
1.1 to 2.2μM. During a 13week general toxicity dog study, sudden
deaths and polymorphic ventricular tachycardia were observed at
a free Cmax of 2.3μM,with PR prolongation as the earliest sign of
impaired cardiac conduction. In healthy volunteers, single doses
of NVP-4 resulted in a mean 16ms PR prolongation that coin-
cided with Tmax. At this dose, the free Cmax was 1.2μM. As a
result of the pre-clinical and clinical ﬁndings and a narrow safety
margin, further development of NVP-4 was discontinued. In this
example, both in vitro assays and dog telemetry data were consis-
tent with and predictive of the clinical ﬁndings in healthy subjects
(Figure 2).
INTEGRATED ASSESSMENT STRATEGY
A schematic of how Novartis currently applies an integrated, step-
wise approach to cardiac sodium channel testing for small mole-
cules during early drug development is outlined in Figure 3. The
ﬁrst step is routine in vitro assessment of ion channel activity based
on automated patch-clamp electrophysiology studies in recombi-
nant expression systems. Automated electrophysiology platforms
enable higher throughput for large-scale screening compared with
manual patch-clamp and therefore, can be utilized in an early
phase of drug discovery such as in lead ﬁnding/lead optimization.
If hNav1.5 blockade is observed, the lead molecule can be opti-
mized to mitigate the hNav1.5 effect at an early stage during lead
optimization with the guidance of in silico tools as exempliﬁed
in Section “In vivo Animal Models.” Manual patch-clamp is used
during the late pre-clinical phase to verify automated patch-clamp
results and obtain more accurate drug concentration data. During
clinical candidate selection, non-rodent in vivo telemetry studies,
typically jacketed dogs and/or monkeys in ascending dose general
toxicity studies, are used to detect potential sodium channel effects
in vivo. Additional pre-clinical assays such as isolated heart models
may be used as needed on a case-by-case basis at any stage, includ-
ing after the compound is tested in man (reverse translation).
During the Investigational New Drug (IND) enabling phase ECGs
are recorded in non-rodent cardiovascular single dose safety phar-
macology studies with implanted electrodes and in repeat dose
toxicity studies with either jackets or external electrodes. At this
stage of development, we consider hNav1.5 inhibition as a safety
signal, whether detected in vitro through patch-clamp assay or
in an isolated heart model, or in vivo using non-rodent teleme-
try models. It is worthwhile to stress that a risk beneﬁt analysis
and an integrated risk assessment must be performed for each
individual molecule. The assessment should address exposure–
response relationships for the compound’s unwanted effect on
depolarization/conduction comparedwith the exposure for its pri-
mary pharmacodynamic and estimated therapeutic effects. Special
consideration should also be given to the anticipated target pop-
ulation, especially patients with pre-existing cardiac risk factors
(e.g., structural heart disease, prior myocardial infarction, etc.) or
known cardiac sodium channel gene variants.
FIGURE 2 | Pre-clinical to clinical translation of sodium channel
inhibition. Overlay plots of NVP-4 concentration–response curves are shown
for effects on PR interval in human subjects, QRS and PR intervals in dogs,
conductance in isolated rabbit hearts, and hNav1.5 current amplitude in
manual patch-clamp. In vivo dog and human data are plotted as maximum
free plasma concentration (Cmax). Plasma protein binding of NVP-4 in humans
and dogs is 77 and 85%, respectively. Vertical dashed line indicates human
free Cmax at efﬁcacious dose (0.67μM).
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FIGURE 3 | Cardiac sodium channel safety assessment schematic.
Non-rodent telemetry includes dog or non-human primates. Safety
margins are calculated by dividing hNav1.5 IC50, lowest effect
concentration in the rabbit heart or free Cmax for lowest efﬁcacious dose
in non-rodent telemetry by free Cmax at estimated efﬁcacious plasma
concentration in human. IND, Investigational New Drug; GLP, Good
Laboratory Practice. Dotted lines indicate case-by-case use (see text for
details).
TRANSLATIONAL VALUE OF THE PRE-CLINICAL
ASSESSMENT AND CLINICAL PERSPECTIVE
As is true for many other cases in drug development, translating
pre-clinical information regarding hNav1.5 into clinically mean-
ingful predictions is challenging. The experience with sodium
channel blocking drugs in the CAST trial taught us that sup-
pression of ventricular premature depolarizations via hNav1.5
blockade was an unsafe and inappropriate therapeutic goal in
patients who had suffered a myocardial infarction. So, the ques-
tion remains: what is an appropriate surrogate to indicate a clinical
safety risk based on hNav1.5 inhibition?
Two commonly used surrogate markers are the PR and QRS
intervals on the ECG. The PR interval represents AV conduction
time, and can be prolonged by hNav1.5 or hCav1.2 blockers. How-
ever, many other factors affect this interval including heart rate
and autonomic tone. In addition, both specialized conduction tis-
sues (sinoatrial node andAV node) and atrial myocytes contribute
to the interval. Although these variables limit the sensitivity and
speciﬁcity of the PR as a surrogate and its ultimate utility as a
safety biomarker, it should not be ignored when prolongation is
detected. The QRS width is also an easily quantiﬁed interval that is
mechanistically linked to hNav1.5 blockade. Harmer et al. (2011)
examined the relationship between hNav1.5 IC50 and QRS widen-
ing in humans and found that aQRS change can be evoked by a free
plasma drug concentration 15-fold less than the corresponding
IC50. Cordes et al., 2009 came to a similar conclusion. The impli-
cation from these analyses is that a relatively small inhibition of
hNav1.5, e.g.,<10%, could be associated with QRS prolongation
in man (Cordes et al., 2009).
What are the clinical implications of QRSwidening via hNav1.5
blockade? The clinical manifestations will depend on speciﬁc
factors such as on/off kinetics, use dependence, dosing regimen,
and individual patient cardiac risk (e.g., those with cardiomyopa-
thy). The true correlation between degree of QRS widening and
hard clinical endpoints (e.g., arrhythmic death) requires large-
scale prospective trials of drugs with hNav1.5 blocking properties
and QRS widening as the dose limiting toxicity. This situation
would allow a risk/beneﬁt assessment and lend insight into what
degree of QRS widening might translate into pro-arrhythmia risk.
In the absence of this type of clinical validation for QRS as
a surrogate marker for hNav1.5 mediated cardiac safety risk and
based on their data, Harmer et al. (2011) have suggested that the
pharmaceutical industry treat the relationship between hNav1.5
inhibition and QRS widening as we have the relationship between
hERG inhibition and QT prolongation. That is, while the QT pro-
longation associatedwith hERGblockade is an imperfect surrogate
for TdP and death, given a choice between a drug that prolongsQT
and one that does not, the prudent choice would be to develop the
latter. Similarly, given the potential for arrhythmic risk with QRS
prolongation, the logical approach would be to remove or mini-
mize hNav1.5 blocking activity in drug candidates before entering
human trials. We agree with this position, particularly since clini-
cal validation of QRS prolongation as a risk biomarker is not likely
to be performed.
LIMITATIONS OF THE STUDY
This study is a work in progress and there are a number of limi-
tations that should be acknowledged. In this review, we focus on
electrophysiological effects of drug–induced hNav1.5 inhibition.
The sodium channel inhibition may have various other cardiovas-
cular effects such as impairment of cardiac contractility. However,
these are not within the scope of this review and therefore are not
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covered. The data sets particularly the clinical data are limited. The
IC50 for hNav1.5 inhibition is used to deﬁne the potency of the
compounds as thismeasure is themost reliable part of the sigmoid
concentration response (Redfern et al., 2003; Harmer et al., 2011).
However, IC10 and/or IC20 values may be more accurate measures
to translate in vitro potency into in vivo effects. Additionally, use of
ratios, when calculating safety margins, mainly deal with the cen-
tral tendency of populations and do not consider outliers. Finally,
the data set presented in this work is limited to low molecular
weight inhibitors of hNav1.5 and the recommendations may not
apply to larger biologic molecules such as therapeutic proteins or
monoclonal antibodies.
SUMMARY AND RECOMMENDATIONS
In contrast to the established meticulous standards required to
characterize IKr inhibition and QT prolongation risk during drug
development, health authorities do not speciﬁcally request charac-
terization of a drug candidate’s effect on hNav1.5 and QRS com-
plex. Thus, these studies are not routinely performed. However,
there is ample evidence that hNav1.5 inhibition poses a signiﬁcant
cardiovascular risk.
Compounds that inhibit hNav1.5 and slow the rate of car-
diac depolarization and conduction (manifested as QRS prolon-
gation) can also cause life-threatening arrhythmias and sudden
cardiac death, although the relationship between QRS widen-
ing and arrhythmias in healthy or diseased hearts is not well
understood (Seger, 2006). Nonetheless, possible safety concerns
regarding cardiac sodium channel inhibition in patients and the
central importance of cardiac adverse effects during the drug
development process make it prudent to identify, eliminate or
minimize this liability early in the drug development process. The
potential for drug-induced inhibition of the cardiac sodium chan-
nel has increasingly gained attention in recent years (Chen et al.,
2009; Harmer et al., 2011). Pharmaceutical companies and con-
tract research laboratories have begun to employ broader screen-
ing against a panel of cardiac ion channels, including hNav1.5.
Recent data from Harmer et al. (2011) showed a good correla-
tion between IC50 values for cardiac sodium channel inhibition in
an automated electrophysiology-based assay and potency for QSR
widening in humans for a wide range of compounds. The Novar-
tis approach starts with in vitro assays for hNav1.5 and expands
the safety assessment to integrate the judicious use of in silico,
in vitro, and in vivo tools. Early data from implementation of
this approach show promising results although the translational
experience is still limited. We believe that a systematic approach
incorporating in vitro assays, in vivo models and in silico model-
ing can provide a better understanding of the effects of cardiac
sodium channel and enable better decision making in early drug
development.
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